文章核心观点 - Praxis Precision Medicines公司股价在上一个交易日上涨6.4%,收于40.11美元,成交量大幅增加[1] - 这一涨幅是由于Praxis的竞争对手Jazz Pharmaceuticals宣布其一项中期试验失败,这增加了Praxis的主要产品候选物ulixacaltamide(PRAX-944)在治疗essential tremor(ET)适应症上的成功可能性[2] - Praxis预计在即将发布的财报中将亏损2.39美元/股,但收入将同比增长114.1%至1.67百万美元[3] 行业和公司研究 - 收益和收入增长预期能反映出股票的潜在实力,但研究表明,收益预测修正趋势与短期股价走势高度相关[4] - 对于Praxis,过去30天内其季度EPS预测没有变化,这意味着如果没有收益预测修正趋势,股价很难持续上涨[5] - Praxis目前被评为中性评级(Zacks Rank 3),而同行业公司Harmony Biosciences也被评为中性[6][7] - Harmony Biosciences最新一个季度的EPS预测较一个月前下降114.8%至-0.04美元,同比下降107.1%[8]

BOSTON, June 04, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on June 3, 2024, the Compensation Committee of Praxis’ Board of Directors granted non- qualified stock option awards to purchase an aggregate of 300 shares of its common stock and restricted s ...

文章核心观点 - 公司是一家临床阶段的生物制药公司,专注于利用遗传洞见开发治疗中枢神经系统(CNS)疾病的疗法 [1] - 公司将参加三个即将到来的会议,包括H.C. Wainwright 2nd Annual BioConnect Investor Conference、Mizuho Securities USA Neuroscience Summit和Jefferies Global Healthcare Conference [1][2][3] - 公司将在这些会议上进行路演和演讲 [1][3] 公司概况 - 公司是一家临床阶段的生物制药公司,专注于利用遗传洞见开发治疗中枢神经系统(CNS)疾病的疗法 [1] - 公司拥有多种治疗运动障碍和癫痫的临床阶段产品候选药物 [4] - 公司利用自有的小分子平台Cerebrum™和antisense寡核苷酸(ASO)平台Solidus™来发现和开发治疗罕见和更常见神经系统疾病的疗法 [4] 会议参与情况 - 公司将参加H.C. Wainwright 2nd Annual BioConnect Investor Conference,在会上进行路演 [1] - 公司将参加Mizuho Securities USA Neuroscience Summit [2] - 公司将参加Jefferies Global Healthcare Conference,在会上进行路演 [3]

BOSTON, May 17, 2024 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will be participating in three upcoming conferences. Praxis management will participate in a fireside chat at the H.C. Wainwright 2nd Annual BioConnect Investor Conference, taking pla ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results Plans to initiate two efficacy studies investigating PRAX-628 in focal onset seizures in the second half of 2024 and first half of 2025, respectively Continued strong recruitment for the pivotal Essential3 trials in Essential Tremor (ET), with over 50,000 pre- screening forms and over 7,000 referrals received to date that meet pre-qualifying eligibility criteria; topline results expected in the second half ...

Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results Over 3,000 referrals received to date meet pre-qualifying eligibility criteria for ulixacaltamide Phase 3 studies in the Essential3 program for essential tremor (ET); enrollment on track to be completed in 1H 2024 with topline results in 2H 2024 Topline results from the PRAX-628 study in epilepsy patients with photo-paroxysmal response (PPR) expected in 1Q 2024; preliminary analysis of 15 mg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from________ to_________ Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (St ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or o ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ For the transition period from to Commission File Number: 001-39620 PRAXIS PRECISION MEDICINES, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-5195942 (State or other ...